JasonWestinMD

PubMed

• Impact of Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation in Non-Hodgkin Lymphoma.
  Clark Andersen, Amy Ayers, Michael L Wang, Francisco Vega, Lynne Nguyen, Lorna McNeill, Kehe Zhang, Cici Bauer, Christopher R Flowers, Chijioke Nze, Jason R Westin, Sw...> ;Blood Advances. 2024 Mar 23
• Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-ce...
  Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sairah Ahmed, David B Miklos, Yi Lin, Brian T Hill, Armin Ghobadi, S...> ;American Journal of Hematology. 2024 May 1
• Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
  Ghobadi, A., Munoz, J., Westin, J., Locke, F., Miklos, D., Rapoport, A., Perales, M., Reagan, P., McGuirk, J., Jacobson, C., Kersten, M., Avivi, I., Peng, A., Schupp, ...> ;Blood Advances. 2024 Feb 5
• Degradation trumps mutations in cancer.
  Davis, R., Westin, J.> ;Science. 2024 Feb 2
• Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system i...
  Fetooh, A., Nair, R., Malpica, L., Wang, M., Lionel, A., Gurumurthi, A., Eldaya, R., Ahmed, S., Iyer, S., Nastoupil, L., Westin, J., Fayad, L., Tummala, S., Flowers, C...> ;Leukemia & Lymphoma. 2024 Jan 22
• Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).
  Filosto, S., Vardhanabhuti, S., Canales, M., Poiré, X., Lekakis, L., de Vos, S., Portell, C., Wang, Z., To, C., Schupp, M., Poddar, S., Trinh, T., Warren, C., Aguilar,...> ;Blood Cancer Discovery. 2024 Jan 8
• Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
  Andrew P Jallouk, Naishu Kui, Ryan Sun, Jason R Westin, Raphael E Steiner, Ranjit Nair, Loretta J Nastoupil, Luis E Fayad, Ajlan Al Zaki, Misha Hawkins, Sherry Adkins,...> ;Haematologica. 2023 Nov 30
• Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 s...
  Max J Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B Hagemeister, Jason R Westin, Felipe Samaniego, Mario L Marques-Piubelli, Francisco Vega Vazquez, Edwin R P...> ;Cancer. 2024 Mar 15
• Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20B Cell Lymphoma.
  Ian W Flinn, Jessica Sachs, Benjamin Exter, Ann Ranger, Patricia Harris, Francis Payumo, Rajneesh Nath, Mehdi Hamadani, Jason R Westin, Veronika Bachanova, Munoz, J., ...> ;Transplantation and Cellular Therapy. 2024 Feb 1
• Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma.
  Anath C Lionel, Jason Westin> ;Current Oncology Reports. 2023 Nov 1
• Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.
  Omar Mamlouk, Paolo Strati, Lei Feng, Ryan Sun, Amy Ayers, Raphael E Steiner, Ranjit Nair, Christopher Flowers, Jeremy L Ramdial, Neeraj Saini, Samer A Srour, Richard ...> ;British Journal of Haematology. 2024 Jan 1
• 3 citations
  A single-cell atlas of CD19 chimeric antigen receptor T cells.
  Xubin Li, Jared Henderson, Max J Gordon, Irtiza Sheikh, Loretta J Nastoupil, Jason Westin, Christopher Flowers, Sairah Ahmed, Linghua Wang, Sattva S Neelapu, Paolo Str...> ;Cancer Cell. 2023 Nov 13
• 6 citations
  Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells.
  Paolo Strati, Xubin Li, Qing Deng, Mario L Marques-Piubelli, Jared Henderson, Grace Watson, Laurel Deaton, Taylor Cain, Haopeng Yang, Vida Ravanmehr, Luis E Fayad, Swa...> ;Cell Reports. Medicine. 2023 Aug 15
• 3 citations
  Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
  Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason Westin, Izidore S Lossos, Javie...> ;Blood Advances. 2023 Oct 24
• 6 citations
  A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
  Paolo Strati, Andrew Jallouk, Qing Deng, Xubin Li, Lei Feng, Ryan Sun, Sherry Adkins, Swapna Johncy, Taylor Cain, Raphael E Steiner, Sairah Ahmed, Dai Chihara, Luis E ...> ;Blood Advances. 2023 Nov 14
• 3 citations
  The race is on: bispecifics vs CAR T cells in B-cell lymphoma.
  Ashwath Gurumurthi, Jason Westin, Marion Subklewe> ;Blood Advances. 2023 Oct 10
• 41 citations
  A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
  Christoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, Viktoria Blumenberg, Maria-Luisa Schubert, Uria Mor, Matthias A Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayas...> ;Nature Medicine. 2023 Apr 1
• 8 citations
  Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
  Jason R Westin, Frederick L Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B Miklos, Matthew L Ulrickson, Miguel-Angel Perales, Umar F...> ;Clinical Cancer Research. 2023 May 15
• 1 citations
  PD-L1macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma.
  Raphael E Steiner, Edwin R Parra, Francisco Vega, Lei Feng, Jason R Westin, Sattva S Neelapu, Paolo Strati, Michael R Green, Christopher R Flowers, Luisa M Solis, Igna...> ;Experimental Hematology & Oncology. 2023 Mar 20
• 15 citations
  Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
  Jason Westin, R Eric Davis, Lei Feng, Fredrick Hagemeister, Raphael Steiner, Hun Ju Lee, Luis Fayad, Loretta Nastoupil, Sairah Ahmed, Alma Rodriguez, Michelle Fanale, ...> ;Journal of Clinical Oncology. 2023 Feb 1
• 32 citations
  Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
  Jin, M., Brian J Sworder, David M Kurtz, Stefan K Alig, Matthew J Frank, Navika Shukla, Andrea Garofalo, Charles W Macaulay, Mohammad Shahrokh Esfahani, Mari N Olsen, ...> ;Cancer Cell. 2023 Jan 9
• 5 citations
  A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
  Hua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, Loretta J Nastoupil, Luis Fayad, Sattva S Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F M Craig, Charle...> ;Blood Advances. 2023 Apr 11
• 8 citations
  Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.
  Paolo Strati, Andrew P Jallouk, Ryan Sun, Jaihee Choi, Kaberi Das, Hua-Jay Cherng, Sairah Ahmed, Hun J Lee, Swaminathan P Iyer, Ranjit Nair, Loretta J Nastoupil, Rapha...> ;Leukemia. 2022 Nov 1
• 5 citations
  Hepatitis E Virus Infection in Cancer Patients.
  Chia-Yu Chiu, Hao Chi Zhang, Jason Westin, Chitra Hosing, Harrys A Torres> ;Transplantation and Cellular Therapy. 2022 Nov 1
• 18 citations
  Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.
  Cherng, H., Sun, R., Sugg, B., Irwin, R., Yang, H., Le, C., Deng, Q., Fayad, L., Fowler, N., Parmar, S., Steiner, R., Hagemeister, F., Nair, R., Lee, H., Rodriguez, M....> ;Blood. 2022 Aug 4
• Join now to see all

Journal Articles

• Assessment of Radiation Doses Delivered to Organs at Risk Among Patients with Early-Stage Favorable Hodgkin Lymphoma Treated with Contemporary Radiation Therapy  
  Chelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, Jason Westin, Simrit Parmar, Loretta Nastoupil, Sattva Neelapu, Bouthaina S Dabaja, JAMA Network Open

Abstracts/Posters

• Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patie...
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-c... 
  2019 ASCO Annual Meeting - 6/1/2019
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all